Skip to main content

Theravance Biopharma sells Respitory Company to Royalty Pharm

Press releases | July 13, 2022

Fried Frank advised Evercore and MTS Partners as financial advisors to Theravance Biopharma in its US$1.5 billion sale to Royalty Pharma all of its units in Theravance Respiratory Company, representing 85% economic interest in the royalty rights on worldwide net sales of GSK's TRELEGY ELLIPTA. 

The Fried Frank team was led by partner Philip Richter.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.